ArticleFrontiers in nutrition2026
Aldosterone-identified targets for optimal sodium and potassium supplementation in intestinal failure.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parenteral support (PS) is a life-saving organ replacement therapy for patients with intestinal failure (IF). However, practical strategies to establish optimal PS sodium and potassium remain poorly defined. We investigated whether elevated plasma renin and aldosterone reflect suboptimal electrolyte supplementation and could help guide physiologically optimal sodium and potassium supplementation in patients with IF. Methods: Real-world monitoring data from adult IF patients receiving long-term PS were analyzed using mixed-effects models for repeated measurements. Associations between parenteral sodium and potassium supplementation, urinary sodium and potassium excretion, and plasma renin and aldosterone were studied across short bowel patients with a jejunostomy (SB-J) or with colon in continuity (SB-CiC). Results: In 618 visits from 110 patients, elevated aldosterone levels occurred frequently and were more common in SB-J (adjusted OR for hyperaldosteronism: 5.2; 95% CI 1.5 to 17.8; Conclusion: Aldosterone not only reflects sodium depletion but is also stimulated to excrete overzealous intravenous potassium supplementation in patients with IF. Targeting a urinary sodium concentration of >20 mmol/L and a urinary sodium-to-potassium ratio of >1 can help to guide physiologically optimal sodium and potassium support in IF. Subsequently, parenteral potassium support of less than 1.0 mmol/kg/d is likely sufficient for most patients with IF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.